abrdn Life Sciences Investors (NYSE:HQL) Shares Break Above 200 Day Moving Average – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $18.21 and traded as high as $18.31. abrdn Life Sciences Investors shares last traded at $18.28, with a volume of 92,971 shares traded.

abrdn Life Sciences Investors Price Performance

The stock has a 50 day moving average of $19.09 and a 200 day moving average of $18.23.

abrdn Life Sciences Investors Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 13.5%. The ex-dividend date was Monday, August 24th.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently made changes to their positions in the company. KPP Advisory Services LLC increased its stake in abrdn Life Sciences Investors by 2.7% in the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after acquiring an additional 660 shares during the last quarter. 180 Wealth Advisors LLC raised its position in abrdn Life Sciences Investors by 2.2% during the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares in the last quarter. Wedbush Securities Inc. lifted its stake in abrdn Life Sciences Investors by 21.1% during the third quarter. Wedbush Securities Inc. now owns 19,335 shares of the company’s stock worth $362,000 after purchasing an additional 3,375 shares during the last quarter. Provenance Wealth Advisors LLC bought a new stake in abrdn Life Sciences Investors during the third quarter worth $66,000. Finally, NewEdge Advisors LLC lifted its stake in abrdn Life Sciences Investors by 17.6% during the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after purchasing an additional 3,562 shares during the last quarter. 32.21% of the stock is currently owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.

Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.

The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla’s investment management activities into abrdn.